Welcome to our dedicated page for NeuroPace SEC filings (Ticker: NPCE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NeuroPace, Inc. SEC filings document the company's medical-device business, Nasdaq-listed common stock and public-company reporting obligations for the RNS System epilepsy therapy. Form 8-K reports cover operating results, financial condition, corporate updates, material agreements, clinical or regulatory disclosures, and executive or compensation-related events.
Proxy filings describe NeuroPace governance matters, including annual meeting proposals, director elections, auditor ratification and stockholder voting mechanics. The filing record also provides formal disclosure on capital structure, officer transitions, separation or consulting arrangements, and risk areas associated with commercialization, clinical evidence and regulatory oversight of neurostimulation devices.
NeuroPace Inc (NPCE) reported an insider tax-withholding transaction by Chief Executive Officer and director Joel Becker. On August 27, 2026, 1,126 shares of common stock were withheld by NeuroPace to satisfy tax withholding obligations arising from the vesting of a restricted stock unit award. Following this withholding transaction, Becker directly held 139,310 shares of NeuroPace common stock.
NeuroPace Inc (NPCE) reported an insider equity withholding transaction by Chief Medical Officer Martha Morrell. On August 27, 2026, 358 shares of common stock were withheld by the company at $14.13 per share to cover tax withholding obligations related to the vesting of a restricted stock unit award. After this withholding, Morrell directly held 51,692 shares of NeuroPace common stock.
NeuroPace, Inc. received an amended institutional ownership report from OrbiMed. OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC each report beneficial ownership of 1,505,125 shares of NeuroPace common stock, representing 4.4% of the outstanding class as of June 30, 2026.
The OrbiMed entities report shared voting and dispositive power over all 1,505,125 shares and no sole voting or dispositive power. They state that the shares are held on behalf of other persons who have rights to dividends and sale proceeds, and that OrbiMed Advisors LLC exercises investment and voting power through a management committee whose members disclaim beneficial ownership of these shares.
NeuroPace, Inc. reported higher sales but continued losses for the quarter ended June 30, 2026. Revenue rose to $22.8 million from $19.5 million a year earlier (up 17%), driven by more RNS System initial implants and replacements. Gross margin remained high at 82.8%, little changed from 83.1%.
Operating expenses were stable overall, with higher sales and marketing spending offset by lower general and administrative costs after prior one-time severance and transition charges. Net loss from continuing operations narrowed to $6.2 million in the quarter and $12.9 million for the first half, compared with $10.0 million and $18.2 million, respectively, in 2025.
Cash, cash equivalents and short‑term investments totaled $51.7 million at June 30, 2026, with net cash used in operating activities of $9.8 million in the first half. Long‑term debt under the MidCap term loan was $59.0 million. The company remained in compliance with liquidity and revenue covenants, supported by $89.2 million in trailing 12‑month net RNS System revenue. NeuroPace also determined its DIXI Medical product line qualifies as a discontinued operation and ceased related sales, simplifying its focus on the RNS System. The FDA, however, informed the company that its Premarket Approval Supplement for a generalized epilepsy label expansion is not approvable in its current form and requested additional information.
NeuroPace, Inc. reported second-quarter 2026 results showing higher revenue and a narrowed loss while remaining unprofitable. Total revenue was $22.8 million, up 17% from $19.5 million a year earlier, driven by RNS System revenue of $22.5 million, which rose 21.3%. Non-GAAP gross margin was 83.4% and GAAP gross margin from continuing operations was 82.8%.
Non-GAAP operating expenses were $21.9 million, yielding a non-GAAP loss from operations of $2.8 million, improved from a $5.0 million loss in 2025. GAAP net loss from continuing operations was $6.2 million versus $10.0 million a year earlier. Cash, cash equivalents, short-term investments and restricted cash totaled $51.9 million as of June 30, 2026, against long-term debt of $59.0 million.
The company increased full-year 2026 guidance to total revenue of $99.5 million to $101.5 million, reflecting higher expected service revenue, and raised its non-GAAP gross margin outlook to 82.0%–83.0%. It maintained non-GAAP operating expense guidance of $90 million–$92 million and now expects Adjusted EBITDA between a loss of $7.5 million and $8.5 million.
NeuroPace, Inc. reported that the FDA informed it that the Premarket Approval Supplement seeking to expand the labeled indication for the RNS System to antiseizure medication-resistant idiopathic generalized epilepsy is not approvable in its current form and requested additional clinical evidence, including more NAUTILUS trial data and literature.
The company plans to submit a Submission Issue Request, amend its filing, and continue working with FDA on a path to approval. NAUTILUS 18‑month results showed a 77% median reduction in generalized tonic-clonic seizures and 40% seizure freedom, with strong patient and physician global improvement scores; 24‑month follow-up in a subset showed a 100% median reduction. Management reiterated that current guidance excludes any contribution from this indication and will discuss the update and full second-quarter 2026 results on an August 11, 2026 call.
NeuroPace Inc’s Chief Medical Officer, Martha Morrell, reported a routine share withholding for taxes. On June 24, 2026, 335 shares of common stock were disposed of at $16.22 per share to satisfy tax withholding obligations tied to a restricted stock unit vesting. After this tax-withholding transaction, she directly holds 52,050 shares of NeuroPace common stock.
NeuroPace director Uri Geiger received a stock award of 789 shares of common stock at $15.63 per share. The shares were issued under the company’s non-employee director compensation policy in lieu of quarterly cash retainer fees, so this is a routine compensation-related acquisition rather than an open-market purchase.
After this award, Geiger holds 18,537 NeuroPace shares directly. Separately, 4,432,948 shares are held indirectly through Accelmed Partners II LP, an entity over which he has sole voting and dispositive power via his role at Accelmed Partners II, LLC.
Fischer Frank M reported acquisition or exercise transactions in this Form 4 filing.
NeuroPace Inc director Frank M. Fischer received 1,467 shares of Common Stock on June 19, 2026. These shares were issued under the company’s non-employee director compensation policy in lieu of quarterly cash retainer fees, bringing his directly held stake to 599,534 shares.
Kumar Rakhi reported acquisition or exercise transactions in this Form 4 filing.
NeuroPace Inc director Rakhi Kumar received a stock grant of 989 common shares, valued at $15.63 per share, as part of non-employee director compensation in lieu of quarterly cash retainer fees. Following this award, Kumar directly holds a total of 23,039 NeuroPace common shares.